A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs TP-3654 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Tolero Pharmaceuticals
- 14 May 2019 According to a Tolero Pharmaceuticals, first patient has been dosed for this study.
- 17 Apr 2019 Status changed from not yet recruiting to recruiting.
- 13 Mar 2019 Planned initiation date changed from 1 Nov 2018 to 26 Mar 2019.